Full Fed. Circ. Won't Undo Sandoz Loss In Patent Fight
By Adam Lidgett (September 29, 2020, 5:20 PM EDT) -- The full Federal Circuit on Tuesday refused Sandoz Inc.'s request to reconsider a panel decision that had upheld two patents covering Amgen's top-selling biologic Enbrel.
The appellate court denied a bid from Sandoz for a panel or en banc rehearing of a precedential July 1 decision that held that Amgen unit Immunex Corp. can't be considered to have patented the same invention twice — once in its own patent and then again in patents it exclusively licenses from Hoffmann-La Roche Inc. — which means the patents can't be invalidated for obviousness-type double patenting.
Sandoz had argued that the panel majority wrongly...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!